Xilio Therapeutics XLO Cash Flow Statement (2020-2026)

NASDAQ XLO
$8.47 -0.06 (-0.70%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Xilio Therapeutics Quarterly Cash Flow Statement

Periods 25 quarters
Latest Sep 2026

Xilio Therapeutics reported cash from operations of -$13.79M and free cash flow of -$12.59M for the quarter ended Sep 2026, up 21.2% year over year. This cash flow statement covers 25 quarters of results from Sep 2020 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-19.70M-21.35M-24.61M-19.79M-22.47M-22.65M-19.36M-16.75M-17.66M-17.20M-13.93M-14.02M-13.09M-13.30M-15.84M-16.29M10.36M-9.53M-6.37M-5.95M
Depreciation and DepletionDep. & Depletion
0.40M0.40M0.40M0.50M0.40M0.50M0.40M0.50M0.40M0.40M0.40M0.40M0.40M0.50M0.40M0.30M0.30M0.30M0.30M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.39M0.44M0.45M0.47M0.49M0.50M0.49M0.46M0.45M0.44M0.45M0.38M0.38M0.50M0.38M0.34M0.32M0.34M0.33M0.32M
Share-based CompensationStock Comp.
2.07M2.03M2.71M1.87M1.82M1.79M1.80M1.86M1.93M1.83M1.51M1.57M1.52M1.54M1.35M1.12M2.93M2.21M1.60M1.92M
Gains from Sales and DivestituresGains Divest
0.00M-0.01M
Other non-cash itemsOther Non-Cash
0.05M0.05M0.05M0.06M0.06M0.03M0.09M0.02M0.02M0.00M0.05M15.38M-21.28M-3.30M3.94M-4.82M
Change in Working Capital
Change in ReceivablesChange Receivables
30.00M-12.50M-5.00M6.00M4.00M
Change in Account PayablesChange Payables
-1.19M-0.82M-0.40M0.25M1.46M-1.36M-0.81M0.54M-0.44M-0.31M0.51M-0.28M1.60M-0.59M2.11M-1.80M0.43M-1.68M1.26M-1.55M
Change in Accrued ExpensesChange Accrued Exp.
0.84M-1.43M4.63M-3.09M1.47M-3.87M0.66M2.28M1.10M-2.50M1.25M-0.21M-0.09M-6.38M1.16M3.31M0.93M-1.54M-1.45M0.98M
Change in Other Operating AssetsOther Assets Change
-0.55M-0.43M-0.62M-0.53M0.84M-0.51M-0.78M1.55M-1.41M1.66M-2.28M-1.15M2.75M-0.96M-2.12M0.50M-0.50M1.21M-0.62M-1.86M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.18M-0.19M-0.20M-0.21M-0.21M-0.21M-0.23M-0.24M-0.24M38.88M-2.11M-2.26M-1.72M46.21M-8.08M-1.57M-8.69M-12.65M-12.69M-9.98M
Other Working Capital ChangesOther WC Changes
0.37M0.24M0.42M0.32M-1.05M0.30M0.55M-1.78M1.17M37.23M0.17M-1.12M-4.47M47.18M-5.97M-2.07M-8.19M-13.85M-12.07M-8.12M
Cash from OperationsCash from Ops.
-17.16M-20.84M-16.76M-19.91M-18.22M-25.25M-16.57M-13.37M-13.43M-10.50M19.95M-13.67M-14.16M28.98M-14.48M-17.50M-2.00M-22.34M-18.76M-13.79M
Investing Activities
Capital ExpendituresCapex
0.38M0.25M0.77M0.33M0.51M0.17M0.32M0.01M0.01M0.02M0.40M0.10M0.56M0.02M-1.21M
Change in Property, Plant and EquipmentChange in PP&E
-0.38M-0.25M-0.77M-0.33M-0.51M-0.17M-0.32M-0.01M-0.01M-0.02M-0.40M-0.10M-0.56M-0.02M1.21M
Cash from Investing ActivitiesCash from Investing
-0.38M-0.25M-0.77M-0.33M-0.51M-0.17M-0.32M-0.01M-0.01M-0.02M-0.40M-0.10M-0.56M-0.02M-0.06M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt RepaymentsLT Debt Repayment
0.02M0.02M0.02M0.02M0.02M1.69M1.13M2.24M1.69M3.35M0.02M0.01M
Net Long-Term Debt Issued (Repaid)Net LT Debt
-0.02M-0.02M-0.02M-0.02M-0.02M-1.69M-1.13M-2.24M-1.69M-3.35M-0.02M-0.01M
Net Debt Issuances and RepaymentsNet Debt Issuance
-0.02M-0.02M-0.02M-0.02M-0.02M-1.69M-1.13M-2.24M-1.69M-3.35M-0.02M-0.01M
Change in Capital Stock
Common Stock IssuedStock Issued
116.60M0.02M0.01M0.05M4.31M-4.27M0.00M0.03M0.01M0.04M35.87M0.00M0.04M0.00M
Net Shares Issued and RepurchasedNet Shares Issued
116.60M0.02M0.01M0.05M4.31M-4.27M0.00M0.03M0.01M0.04M35.87M0.00M0.04M0.00M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
116.60M0.02M0.01M0.05M4.31M-4.27M0.00M0.03M0.01M0.04M35.87M0.00M0.04M0.00M
Other financing activities (as filed)
-1.55M
Cash from Financing ActivitiesCash from Financing
115.83M-0.01M-0.02M-0.02M-0.02M-1.69M-0.99M-2.24M-1.63M0.95M20.04M0.00M8.20M4.83M47.36M-0.29M35.87M35.71M4.49M
Additional items
Change in Cash
98.29M-21.09M-17.55M-20.26M-18.75M-27.11M-17.88M-15.61M-15.06M-9.55M39.98M-13.68M-5.96M33.79M32.48M-17.78M33.77M12.81M-14.29M-13.85M
Ending Cash Balance
199.61M178.51M160.96M140.70M121.95M94.84M76.96M61.35M46.29M36.74M76.72M63.03M57.07M90.86M123.35M105.57M139.34M152.15M137.86M1.83M
Free Cash FlowFCF
-17.54M-21.09M-17.53M-20.24M-18.73M-25.42M-16.89M-13.37M-13.43M-10.50M19.95M-13.68M-14.16M28.96M-14.88M-17.50M-2.09M-22.90M-18.78M-12.59M
Net Cash FlowNCF
98.29M-21.09M-17.55M-20.26M-18.75M-27.11M-17.88M-15.61M-15.06M-9.55M40.00M-13.68M-5.96M33.79M32.48M-17.78M33.77M12.81M-14.29M-13.85M
Interest Paid
0.12M0.12M0.12M0.14M0.18M0.21M0.12M0.14M0.10M0.06M

Xilio Therapeutics Cash Flow Statement API

Pull Xilio Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=XLO&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY